Enoblituzumab

Drug Profile

Enoblituzumab

Alternative Names: Fc-optimized humanised anti-B7-H3 monoclonal antibody; MGA-271

Latest Information Update: 21 Feb 2017

Price : $50

At a glance

  • Originator MacroGenics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD276 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Malignant melanoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer

Most Recent Events

  • 01 Dec 2016 Phase-I clinical trials in Solid tumours (In adolescents, In children, In infants, In adults, Second-line therapy or greater) in USA (IV) (NCT02982941)
  • 30 Nov 2016 MacroGenics plans a phase I trial for Solid tumours (Second-line therapy or greater, In infants, In children, In adolescents, In adults) in USA (IV) (NCT02982941)
  • 30 Sep 2016 Sidney Kimmel Comprehensive Cancer Center plans a pilot phase 0 trial for Prostate cancer (Neoadjuvant therapy) in USA (IV) (NCT02923180)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top